免疫检查点抑制剂（ICIs）在临床实践中对多种癌症表现出显着的疗效。然而，ICIs会引起免疫检查点抑制剂相关的胰腺损伤，常常导致停药，然后患者必须接受专门治疗。患者的原发肿瘤对 ICI 治疗敏感，可能会因此类不良反应而导致治疗延误。因此，需要对免疫相关胰腺毒性进行系统的临床研究，为其预防和治疗提供临床依据。本研究收集了接受ICIs治疗的患者的数据，并在继续ICIs治疗前通过先发制人的治疗来解决胰腺损伤问题。然后，我们还统计分析了不同疗程和联合治疗的患者胰腺损伤的发生率以及再挑战治疗的成功率。该研究纳入了62名患者，其中33.9%（21/62）经历了不同程度的胰腺损伤。胰腺损伤患者中，10例发展为胰腺炎，占胰腺损伤亚组的47.6%（10/21），占患者总数的16.1%（10/62）。对47.6%（10/21）的胰腺炎患者进行了抢先治疗，有效率100%。在这些患者中，70% (7/10) 成功接受了 ICI 的再挑战。胰腺损伤的发生与治疗时间呈正相关（P<0.05），但与联合治疗无显着相关性（P>0.05）。随着ICIs治疗时间的延长，胰腺损伤的可能性增加；未发现 ICI 相关胰腺损伤的发生率与联合治疗之间存在显着关联。免疫相关性胰腺炎的先发性治疗是可行的，允许一些患者成功接受 ICI 治疗的再挑战。© 2024。作者获得 Federación de Sociedades Españolas de Oncología (FESEO) 的独家许可。

Immune checkpoint inhibitors (ICIs) have shown remarkable efficacy against various cancers in clinical practice. However, ICIs can cause immune checkpoint inhibitor-associated pancreatic injury, often leading to drug withdrawal, and then patients must go to specialized treatment. The patients, their primary tumors are sensitive to ICIs therapy, may experience treatment delays due to such adverse reactions. Therefore, there is a need for systematic clinical researches on immune-related pancreatic toxicity to provide a clinical basis for its prevention and treatment.This study involved the collection of data from patients treated with ICIs and addressed pancreatic injury with preemptive treatment before continuing ICIs therapy. Then, we also statistically analyzed the incidence of pancreatic injury in patients with different courses and combined treatment, and the success rate of rechallenge treatment.The study included 62 patients, with 33.9% (21/62) experiencing varying degrees of pancreatic injury. Patients with pancreatic injury, 10 cases evolved into pancreatitis, representing 47.6% (10/21) in the pancreatic injury subgroup and 16.1% (10/62) of the total patient cohort. Preemptive treatment was administered to 47.6% (10/21) of patients with pancreatitis, the effective rate was 100%. Among these patients, 70% (7/10) underwent successful rechallenge with ICIs. The occurrence of pancreatic injury was positively correlated with the treatment duration (P < 0.05) but showed no significant correlation with combination therapies (P > 0.05).The likelihood of pancreatic injury increased with longer treatment durations with ICIs; no significant association was found between the incidence of ICIs-related pancreatic damage and combination therapies. Preemptive treatment for immune-related pancreatitis is feasible, allowing some patients to successfully undergo rechallenge with ICIs therapy.© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).